Drug Database
Back to search

Switzerland· 55269002

Visudyne, Pulver zur Herstellung einer Infusionslösung

A verteporfin product containing verteporfinum, registered in Switzerland by Cheplapharm Schweiz GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC S01LA01

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVisudyne, Pulver zur Herstellung eine…ATCS01LA01REGISTER NO.55269002PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about verteporfinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Verteporfin is registered in 15 of 19 countries.

Countries holding a registration under ATC S01LA01 (verteporfin), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose
Search verteporfin products by name

Verteporfin · ATC S01LA01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
verteporfinum
Manufacturer
Cheplapharm Schweiz GmbH
Country
Switzerland (CH)
ATC code
S01LA01
ATC class
Verteporfin
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680552690022
    Durchstf 1 Stk
    CHF 1157.2

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

166 interactions on record for verteporfin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check verteporfin against other medicinesHow interaction checks work

Verteporfin · interactions on record

166 records

  • 1 severe
  • 144 moderate
  • 2 minor
  • 19 info

Most severe, free to view

  • Aminolevulinic acidL01XD04severe
  • TetracyclineA01AB13moderate
  • DoxycyclineA01AB22moderate
  • MinocyclineA01AB23moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Verteporfin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All verteporfin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Visudyne
  • Liechtenstein · Visudyne
  • Norway · Visudyne

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b3d57f08-306e-49ee-9b48-a4b03c1fe377
GET /v1/drugs/b3d57f08-306e-49ee-9b48-a4b03c1fe377?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "verteporfinum 15 mg",
  "valid_from": "2004-01-01",
  "limitations": "[{\"description\":\"Maximal vier Behandlungen pro Jahr.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2007-01-01\"}]",
  "galenic_form": "Trockensub 15 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2000-04-15",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about verteporfin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console